The CD20 expression in CLL is significantly lower than in most histological types of mature B-cell lymphomas in which it appears to be very comparable. Approximately 25% of B-cell lymphoma patients have the CD20 expression below the cut-off value of 25 000 MESF showing that the low CD20 expression might be more common than presumed from our previous study (17.5%).
COBISS.SI-ID: 1085563
Tolerability to gemcitabine radiochemotherapy was evaluated in 33 patients with inoperable, locally advanced transitional-cell bladder cancers. The dose of 75 mg/m2 gemcitabine once a week, concurrently with standard radiotherapy of 60 Gy/6weeks, was found to be acceptable. Eighty-one percentage of 3-year local progression-free survival suggests efficiency warranting further studies.
COBISS.SI-ID: 1227387
Bevacizumab is similary efficacious and well tolerated when administred with XELIRI or FOLFIRI.
COBISS.SI-ID: 1099899